Table 4. Actual chemotherapy (safety population) and five most frequently prescribed regimens in the anthracycline and non-anthracycline groups.
| Actual chemotherapy | No. (%) of patients | ||||
|---|---|---|---|---|---|
| T monotherapy (n=12) |
T combination (n=626) |
T sequential (n=927) |
T/H combination (n=41) |
T/H sequential (n=106) |
|
| Overall | 12 (0.7) | 626 (36.6) | 927 (54.1) | 41 (2.4) | 106 (6.2) |
| Anthracycline | - | 328 (19.2) | 922 (53.9) | 0 | 103 (6.0) |
| Five most frequent specific regimens | TEC: 136 (7.9) | AC-T: 500 (29.2) | - | FEC-TH: 54 (3.2) | |
| TAC: 127 (7.4) | FEC-T: 250 (14.6) | AC-TH: 22 (1.3) | |||
| TE: 21 (1.2) | EC-T: 84 (4.9) | EC-TH: 14 (0.8) | |||
| TA: 44 (2.6) | FAC-T: 33 (1.9) | TH-FEC: 6 (0.4) | |||
| TC+THP: 9 (0.5) | T-FEC: 11 (0.6) | FAC-TH: 3 (0.2) | |||
| Non-anthracycline | - | 298 (17.4) | 5 (0.3) | 41 (2.4) | 3 (0.2) |
| Five most frequent specific regimens | TC: 269 (15.7) | T+DDP-TCb: 2 (0.1) | TCbH: 30 (1.8) | Each other agent (TC-TCH, TCH-TCbH, and TCbH-TH) selected for single patients only | |
| TX: 11 (0.6) | NC-T: 1 (0.1) | TH: 7 (0.4) | |||
| T+DDP: 3 (0.2) | T-TC: 1 (0.1) | TCH: 4 (0.2) | |||
| TCb: 5 (0.3) | TC-TFC: 1 (0.1) | ||||
| TFCM: 6 (0.4) | |||||
T=docetaxel/Taxotere®; H=Herceptin (trastuzumab); E=epirubucin; C=cyclophosphamide; A=adriamycin; THP=pirarubicin; F=5-fluorouracil; X=capecitabine; DDP=cisplatin; Cb=carboplatin; M=methotrexate.